Quest Diagnostics to offer US FDA-approved Fujirebio blood test for Alzheimer's disease: Secaucus, New Jersey Friday, July 11, 2025, 14:00 Hrs [IST] Quest Diagnostics, a leader in ...

An alternative diagnostic method could improve early detection and treatment of peripheral artery disease (PAD), according to ...

Blood proteomics is the study of proteins in blood plasma and is used in everything from cancer treatments to identifying ...

Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, including advanced diagnostics for brain health, today announced it plans to offer laboratory testing based on the ...

After decades of research, the U.S. Food and Drug Administration (FDA) has approved a test that can detect the buildup of amyloid plaques in the brain—a key marker of Alzheimer’s disease, ...

Indiana University School of Medicine researcher Jeff Dage’s years of research into biomarkers helped lead to a first-of-its-kind blood test to diagnose Alzheimer’s disease.

In patients showing cognitive decline, a new blood test for Alzheimer's is expected to make diagnosis more convenient, accessible and inexpensive than other existing tests.

The Lumipulse test has specifically been approved to help diagnose the disease in the clinical setting. Dr. Amanada Smith said that makes it the first and only test with that advantage.

The FDA’s approval of Fujirebio’s ‘Lumipulse G,’ a blood test with over 90% accuracy, can now be used by doctors to determine whether someone has a build-up of amyloid plaques in their brain.

The U.S. Food and Drug Administration cleared the first in vitro diagnostic device that tests blood to aid in diagnosing Alzheimer’s disease. It’s got quite the name. The Lumipulse G pTau217 ...

What makes this blood test so revolutionary The Lumipulse G test works by measuring two specific proteins in your blood plasma that directly correlate with amyloid plaques in your brain.

Amyloid plaque, a feature of Alzheimer's disease, accumulates outside neurons. A new blood test, Lumipulse, measures two subtypes of tau and amyloid proteins, of which certain levels can predict ...